Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Investors Optimistic On FDA Panel For Novo’s Insulin Degludec

Oct 09 2012

• By Emily Hayes

Related Content

Novo Highlights Degludec's Advantage Versus Lantus In Fewer Night-Time Hypoglycemic Events

Dec 30 2010

Degludec Advisory Committee Is Another De Facto Delay For Novo

Jul 18 2012

FDA Clears Victoza, But Warnings And More Studies Pose Hurdles

Feb 01 2010

For Some, Oral Insulin’s Allure Persists Despite Hurdles

Aug 01 2011

New Long-Acting Insulin Offerings Could Derail Lantus Franchise

Jun 18 2012

FDA Diabetes Guidance Encourages Enrollment Of Sicker Patients

Dec 17 2008

Related Companies

Novo Nordisk A/S

Sanofi

Additional Topics

Clinical Trials Regulation

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window